Voyageur Advances Mine-to-Bottle Strategy for Critical Mineral Barium and Iodine Contrast Products

Prices for pharmaceutical-grade barium sulfate “are up over 40-50 percent in just a few months,” Brent Willis said, citing a jump from C$7,300 to “over C$10,000” per tonne at Voyageur Pharmaceuticals’ Calgary facility. The surge has only sharpened the company’s resolve to build a mine-to-medicine supply chain that can insulate North America from foreign dependence.Voyageur’s Frances Creek deposit in British Columbia is the fulcrum of that plan. “China only allowed to export five percent of their pharmaceutical-grade barium sulfate,” Willis noted, underscoring why his team is fast-tracking Frances Creek, whose naturally high purity could displace synthetic alternatives. By pairing the ore body with third-party GMP production today and a future in-house plant, Voyageur aims to realize its motto “from Earth to the bottle.”The strategy is already translating into distribution footprints. Latin America, grappling with chronic shortages of barium contrast media, became the latest target this week. Voyageur is signing regional wholesalers who will “distribute out to their markets” once product rolls off the Canadian line, positioning the company as a streamlined wholesaler until full vertical integration is achieved. Canada is further ahead: provincial health authorities and private clinics are evaluating initial batches, and a larger run scheduled for August will support “more and more sales being announced.”In the United States, Voyageur is preparing an FDA 505(b)(2) submission before year-end, a pathway that avoids human trials by improving on existing drugs. “Our goal is to be selling in Q4 of next year into the U.S. market,” Willis said, eyeing radiology’s richest address.While barium anchors the near term, iodine could unlock even larger margins. In Oklahoma’s Anadarko Basin, Voyageur has wells identified and a partnership with extraction specialist Altillion Inc. to produce 99 percent-pure crystalline I₂. A 200-tonne pilot plant will feed a planned pharmaceutical campus in northern Texas, positioning the company to become “the first I-9 drug producer in the U.S.” and to cut manufacturing costs by as much as 50 percent through full vertical control. “GE Healthcare has tied up the majority of the world’s supply,” Willis explained. “We will be able to secure that supply chain for the North American market.”Shareholders can expect a busy quarter. Voyageur is “in discussions with multinationals” interested in both iodine and barium assets, an FDA filing is on schedule, and new sales contracts should follow production expansion. “Our vertical-integration strategy is resonating with big-pharma people,” Willis said, betting that as critical mineral demand climbs, owning both the rock and the recipe will pay disproportionate dividends.